FDA Greenlights Phase 2 for HER2+ Cancer
Imagion Biosystems, headquartered in Melbourne, Australia, has received approval from the US Food and Drug Administration (FDA) to proceed with Phase 1b/2 clinical trials of its MagSense® Imaging Agent for HER2+ breast cancer as of June 2, 2026. This approval marks a significant advancement for the company’s molecular MRI technology, which utilises non-radioactive nanoparticles for early cancer detection.
With the FDA’s “Study May Proceed” letter, the trial will confirm the safety profile (Phase 1b) and evaluate the efficacy of detecting nodal metastases (Phase 2) in patients with HER2+ breast cancer. “This is a major win for our team and partners and an important milestone for the company. Molecular MRI could be a true breakthrough in medical imaging,” Ward Detwiler, President of Imagion Biosystems, expressed.
Trial Details and Future Applications
Dr. Mohammad Eghtedari, section chief of Women’s Imaging at City of Hope Cancer Centre in Los Angeles, will serve as the trial’s principal investigator. Known for his expertise in diagnostic radiology, Dr. Eghtedari previously participated as an independent reviewer of MagSense® in the company’s Phase I trial.
Insights into healthcare costs, patient outcomes, and clinical value are expected from this trial, with potential data supporting AI diagnostic tools. MagSense® offers increased imaging specificity, crucial for distinguishing between benign and malignant tumors. Conventional imaging often identifies regions using anatomical features but lacks molecular specificity, which MagSense® addresses effectively.
Imagion Biosystems has also conducted pre-clinical studies on imaging agents targeting prostate and ovarian cancers, with plans for further IND-enabling studies. The MagSense® technology utilises targeted nanoparticles to increase imaging specificity, making it easier for clinicians to make accurate diagnoses.
Beyond breast cancer, the platform’s applications extend to other cancers, as Imagion has tested additional agents for prostate and ovarian cancers. This trial will explore its impact on healthcare costs and patient outcomes, paving the way for advancements in medical imaging.
Last updated: 3 June 2026, 5:15 am
